NDC 70713-203-06

This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.

Requested NDC: 70713-203-06
Product root: 70713-203
Identity scope: Package
Primary current NDC product row: Not present

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
compounder	package	70713-203	70713-203-06	COMPOUNDER	Outsourcing facility compounded drug report	2020-2	2026-10-13
compounder	package	70713-203	70713-203-06	COMPOUNDER	Outsourcing facility compounded drug report	2020-1	2026-10-13

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 3 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Archive	Snapshot	Source SHA-256
2025-08-27 00:00 UTC · source 2025-08-20	compounder	package	70713-203	70713-203-06	COMPOUNDER	Outsourcing facility compounded drug report	2020-2	compounder / compounders_ndc_directory.zip	`af8e9b524e63…`	`ca326a94a5e9…`
2025-08-27 00:00 UTC · source 2025-08-20	compounder	package	70713-203	70713-203-06	COMPOUNDER	Outsourcing facility compounded drug report	2020-1	compounder / compounders_ndc_directory.zip	`af8e9b524e63…`	`ca326a94a5e9…`
2022-05-13 07:20 UTC · source 2022-04-19	compounder	package	70713-203	70713-203-06	COMPOUNDER	Outsourcing facility compounded drug report	2022-1	compounder / compounders_ndc_directory.zip	`4694734df12d…`	`db2bf3a0aaab…`

Compounder NDC reports#

Browse the complete compounder directory for this NDC · Browse every current compounder row in the unified auxiliary catalog · browse compounder source captures and parsed snapshots.

Establishment, FEI, Product NDC table
Establishment	Product NDC	Package NDC	Product	Active ingredients	Reporting period	Normalization
"Wells Pharmacy, Inc(057193721)"	70713-203	70713-203-06	Alprostadil; Phentolamine Mesylate; Papaverine Hydrochloride; Atropine Sulfate	30 ug/1 mL; 3 mg/1 mL; 30 mg/1 mL; .1 mg/1 mL	2020-2	valid
"Wells Pharmacy, Inc(057193721)"	70713-203	70713-203-06	Alprostadil; Phentolamine Mesylate; Papaverine Hydrochloride; Atropine Sulfate	30 ug/1 mL; 3 mg/1 mL; 30 mg/1 mL; .1 mg/1 mL	2020-1	valid
"Wells Pharmacy, Inc(057193721)"	70713-203	70713-203-05	Alprostadil; Phentolamine Mesylate; Papaverine Hydrochloride; Atropine Sulfate	30 ug/1 mL; 3 mg/1 mL; 30 mg/1 mL; .1 mg/1 mL	2020-1	valid
"Wells Pharmacy, Inc(057193721)"	70713-203	70713-203-05	Alprostadil; Phentolamine Mesylate; Papaverine Hydrochloride; Atropine Sulfate	30 ug/1 mL; 3 mg/1 mL; 30 mg/1 mL; .1 mg/1 mL	2019-2	valid

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.